Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia

Alzheimer's Disease Neuroimaging Initiative; DESCRIPA working group; INSIGHT-preAD study group; SCD-I working group

doi:10.1016/j.jalz.2018.10.003

Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia

Alzheimer's Disease Neuroimaging Initiative
, DESCRIPA working group
, INSIGHT-preAD study group
, SCD-I working group

Clinical Neuropsychology

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Introduction: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non-AD dementia and (2) determinants of progression to dementia. Methods: Eleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated dementia incidence and identified risk factors using Cox proportional hazards models. Results: In SCD, incidence of dementia was 17.7 (95% Poisson confidence interval 15.2-20.3)/1000 person-years (AD: 11.5 [9.6-13.7], non-AD: 6.1 [4.7-7.7]), compared with 14.2 (11.3-17.6) in controls (AD: 10.1 [7.7-13.0], non-AD: 4.1 [2.6-6.0]). The risk of dementia was strongly increased in SCD in a memory clinic setting but less so in a community-based setting. In addition, higher age (hazard ratio 1.1 [95% confidence interval 1.1-1.1]), lower Mini–Mental State Examination (0.7 [0.66-0.8]), and apolipoprotein E ε4 (1.8 [1.3-2.5]) increased the risk of dementia. Discussion: SCD can precede both AD and non-AD dementia. Despite their younger age, individuals with SCD in a memory clinic setting have a higher risk of dementia than those in community-based cohorts.

Original language	English
Pages (from-to)	465-476
Number of pages	12
Journal	Alzheimer's and Dementia
Volume	15
Issue number	3
Early online date	13 Dec 2018
DOIs	https://doi.org/10.1016/j.jalz.2018.10.003
Publication status	Published - Mar 2019

Funding

This work was supported by the Alzheimer's Association and the International Society to Advance Alzheimer's Research and Treatment (ISTAART) Subjective Cognitive Decline Professional Interest Area (PIA). The authors are grateful to Keith Fargo and April Ross (ISTAART) for facilitating SCD PIA meetings. R. Slot and S. Verfaillie are supported by a research grant from Gieske-Strijbis Fonds. W.M. van der Flier holds the Pasman chair. F. Jessen and S. Sikkes is recipient of JPND - EURO-SCD (grant no: JPND_PS_FP-689-019). The Alzheimer Center Amsterdam is supported by Alzheimer Nederland and Stichting VUmc fonds. The authors thank the collaborators from the DESCRIPA study for their work in the collection of the data. The DESCRIPA study group members include the following individuals: Mercè Boada, Fundació ACE, Barcelona, Spain; Peter Paul de Deyn, Institute Born Bunge, ZNA Middelheim, University of Antwerp, Antwerp, Belgium; Roy Jones, The Research Institute for the Care of Older People, Bath, UK; Giovanni Frisoni, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy, and University Hospital and University of Geneva, Geneva, Switzerland; Luiza Spiru, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; Flavio Nobili, Clinical Neurophysiology Service, Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Genova, Italy; Yvonne Freund-Levi, Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Hilkka Soininen, Institute of Clinical Medicine, Neurology, University of Eastern Finland and Neurocenter, Neurology, Kuopio University; Frans Verhey, Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, The Netherlands; Åsa K. Wallin, Lund University, Clinical Sciences Malmö, Clinical Memory Research Unit, Lund, Sweden; Jacques Touchon, Institute National de la Santé et de la Recherche Medicinale INSERM U 888, Montpellier, France; Marcel Olde Rikkert, Department of Geriatrics, Radboud University Medical Centre, Nijmegen, The Netherlands; Anne-Sophie Rigaud, Department of Geriatrics, Hopital Broca, Paris, France; Roger Bullock, Kingshill Research Centre, Swindon, UK; Magda Tsolaki, Aristotle University of Thessaloniki, Memory and Dementia Center, 3rd Department of Neurology, “G Papanicolaou” General Hospital, Thessaloniki, Greece; Bruno Vellas, Department of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, Toulouse, France; Gordon Wilcock, Department of Care of Elderly, University of Bristol, Frenchay Hospital, Bristol, UK; Harald Hampel, Université Pierre et Marie Curie-Paris 6, AP-HP, Hopital de la Salpetrière, Paris, France; Lutz Froelich, Department of Geriatric Psychiatry, Zentralinstitut fur Seelische Gesundheit, University of Heidelberg, Mannheim, Germany. The authors acknowledge the sharing of data by the INSIGHT-preAD study and thank the INSIGHT-preAD collaborators for their work. The INSIGHT-preAD study group includes Hovagim Bakardjian, Habib Benali, Hugo Bertin, Joel Bonheur, Laurie Boukadida, Nadia Boukerrou, Enrica Cavedo, Patrizia Chiesa, Olivier Colliot, Bruno Dubois, Marion Dubois, Stéphane Epelbaum, Geoffroy Gagliardi, Remy Genthon, Marie-Odile Habert, Harald Hampel, Marion Houot, Aurélie Kas, Foudil Lamari, Marcel Levy, Simone Lista, Christiane Metzinger, Fanny Mochel, Francis Nyasse, Catherine Poisson, Marie-Claude Potier, Marie Revillon, Antonio Santos, Katia Santos Andrade, Marine Sole, Mohmed Surtee, Michel Thiebaud de Schotten, Andrea Vergallo, Nadjia Younsi. INSIGHT-preAD Scientific Committee Members: Dubois B, Hampel H, Bakardjian H, Benali H, Colliot O, Habert Marie-O, Lamari F, Mochel F, Potier MC, Thiebaut de Schotten M. S. Vos receives research support from ZonMw . The DESCRIPA study was supported by the European Commission within the 5th Framework Program, contract number QLK-6-CT-2002-02455. The German DCN study has been supported by a grant from the German Federal Ministry of Education and Research (BMBF): Kompetenznetz Demenzen (01GI0420). The HELIAD study has been supported by the following grants: IIRG-09-133014 from the Alzheimer's Association; 189 10276/8/9/2011 from the ESPA-EU program Excellence Grant (ARISTEIA), which is cofunded by the European Social Fund and Greek National resources, DY2b/oij.51657/14.4.2009 from the Ministry for Health and Social Solidarity (Greece). N.A. Kochan and the Sydney Memory and Ageing Study were supported by grants from the National Health and Medical Research Center, Australia (350833, 1053804). The INSIGHT-preAD study was promoted by INSERM in collaboration with ICM , IHU-A-ICM and Pfizer and has received support within the “Investissement d'Avenir” (ANR-10-AIHU-06) program. The study was promoted in collaboration with the “CHU de Bordeaux” (coordination CIC EC7), the promoter of Memento cohort, funded by the Foundation Plan-Alzheimer. The study was further supported by AVID/ Lilly . H. Hampel is supported by the AXA Research Fund , the “Fondation partenariale Sorbonne Université” and the “Fondation pour la Recherche sur Alzheimer”, Paris, France. Ce travail a bénéficié d'une aide de l'Etat “Investissements d'avenir” ANR-10-IAIHU-06. The research leading to these results has received funding from the program “Investissements d'avenir” ANR-10-IAIHU-06 (Agence Nationale de la Recherche-10-IA Agence Institut Hospitalo-Universitaire-6). This Manuscript benefited from the support of the Program “PHOENIX” led by the Sorbonne University Foundation and sponsored by la Fondation pour la Recherche sur Alzheimer. Dr. Barry Reisberg's work on the project was supported in part by United States Department of Health and Human Services (DHHS) grants AG08051 and AG03051 for the National Institute on Aging , of the US National Institutes of Health , and by the Hagedorn Fund, the Stringer Foundation, the Louis J. Kay and June E. Kay Foundation, donations from Mrs. Miriam Glanbach and Dr. Felix Glanbach, and by a Clinical Research Development Fund of the New York University School of Medicine . A. Saykin and the Indiana Memory and Aging Study (IMAS) were supported by grants from the National Institute on Aging (P30 AG010133, R01 AG019771); S. Risacher was additionally supported by NIA K01 AG049050. ADNI data and sharing were funded by the Alzheimer's Disease Neuroimaging Initiative ( National Institutes of Health Grant U01 AG024904) and DOD ADNI ( Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging , the National Institute of Biomedical Imaging and Bioengineering , and through contributions from Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Araclon Biotech, BioClinica, Inc. , Biogen Idec Inc., Bristol-Myers Squibb Company , Eisai Inc., Elan Pharmaceuticals, Inc., Eli Lilly and Company , EuroImmun, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc., Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immunotherapy Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Medpace, Inc., Merck & Co., Inc., Meso Scale Diagnostics, LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc., Piramal Imaging, Servier, Synarc Inc., and Takeda Pharmaceutical Company.

Funders	Funder number
AXA Research Fund
Agence Nationale de la Recherche
Gieske-Strijbis Fonds
Neurotrack Technologies
Eisai
Institute of Clinical Medicine, Neurology, University of Eastern Finland and Neurocenter
GE Healthcare
Small Business Innovation Research
Harald Hampel, Universit?
Association Sorbonne Université
Fondation Plan Alzheimer
Merck
BioClinica
NeuroRx Research
Piramal Neuroimaging
Novartis Pharmaceuticals Corporation
Cytox Ltd.
Fujirebio Europe
Euroimmun
NIA SBIR
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Frenchay Hospital
Kuopio University
International Society to Advance Alzheimer's Research and Treatment
Synarc Inc.
Université de Genève
Karolinska University Hospital Huddinge
Boehringer Ingelheim
National Institute of Biomedical Imaging and Bioengineering
Department of Geriatric Psychiatry, Zentralinstitut fur Seelische Gesundheit, University of Heidelberg
Fondation partenariale Sorbonne Universit??
Alzheimer Nederland
Takeda Pharmaceutical Company
Biogen
Janssen Stellar
University Hospital
National Health and Medical Research Center, Australia
Eli Lilly and Company
Hagedorn Fund
IXICO
National Institutes of Health
European Commission
Radboud Universitair Medisch Centrum
Magda Tsolaki, Aristotle University of Thessaloniki
Centre Hospitalier Universitaire de Bordeaux
Toulouse University Hospital
Vrije Universiteit Amsterdam
EU-FP7
Fondation pour la Recherche sur Alzheimer
Karolinska Institutet
Foundation Plan-Alzheimer
Roche
ZonMw
Division of Clinical Geriatrics
Ministry of Health and Social Solidarity, Greece
ESPA-EU
Department of Internal Medicine and Clinical Gerontology
Fondation pour la Recherche sur Alzheimer?
Alzheimer Centre Limburg
Johnson & Johnson Pharmaceutical Research & Development LLC, Medpace, Inc.
Piramal Imaging
Università degli Studi di Genova
Elan Pharmaceuticals, Inc.
Bristol-Myers Squibb
Roche BV
Universiteit Antwerpen
Stringer Foundation
Servier
Universitatea de Medicină şi Farmacie din Tîrgu Mureș
DOD ADNI
University of Bristol
Nutricia and Takeda
Pfizer
Sorbonne University Foundation
Intercollegiate Center for Management Science
Genentech
Maastricht University, School for Mental Health and Neuroscience
European Social Fund and Greek National resources	DY2b/oij.51657/14.4.2009
National Institute on Aging	U01AG024904, P30AG010133, R01AG003051, P30AG008051, K01AG049050, R01AG019771
Alzheimer's Disease Neuroimaging Initiative	U01 AG024904
School of Medicine, New York University	P30 AG010133, R01 AG019771
National Health and Medical Research Council	350833, 1053804
Investissements d'avenir	ANR-10-IAIHU-06
Bundesministerium für Bildung und Forschung	01GI0420
European Commission within the 5th framework program	QLK-6-CT-2002-02455
Gieskes-Strijbis Fonds	JPND_PS_FP-689-019
U.S. Department of Health and Human Services	AG08051, AG03051
Alzheimer's Association	189 10276/8/9/2011
U.S. Department of Defense	W81XWH-12-2-0012
Institut national de la santé et de la recherche médicale	ANR-10-AIHU-06

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Alzheimer's disease
Dementia incidence
Dementia Lewy bodies
Frontotemporal dementia
Preclinical Alzheimer's disease
Subjective cognitive decline
Vascular dementia

Access to Document

10.1016/j.jalz.2018.10.003

Persistent URL (handle)

Persistent link

Cite this

@article{dd3639ca9cd84f05b85a60966f982a65,

title = "Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia",

abstract = "Introduction: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non-AD dementia and (2) determinants of progression to dementia. Methods: Eleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated dementia incidence and identified risk factors using Cox proportional hazards models. Results: In SCD, incidence of dementia was 17.7 (95\% Poisson confidence interval 15.2-20.3)/1000 person-years (AD: 11.5 [9.6-13.7], non-AD: 6.1 [4.7-7.7]), compared with 14.2 (11.3-17.6) in controls (AD: 10.1 [7.7-13.0], non-AD: 4.1 [2.6-6.0]). The risk of dementia was strongly increased in SCD in a memory clinic setting but less so in a community-based setting. In addition, higher age (hazard ratio 1.1 [95\% confidence interval 1.1-1.1]), lower Mini–Mental State Examination (0.7 [0.66-0.8]), and apolipoprotein E ε4 (1.8 [1.3-2.5]) increased the risk of dementia. Discussion: SCD can precede both AD and non-AD dementia. Despite their younger age, individuals with SCD in a memory clinic setting have a higher risk of dementia than those in community-based cohorts.",

keywords = "Alzheimer's disease, Dementia incidence, Dementia Lewy bodies, Frontotemporal dementia, Preclinical Alzheimer's disease, Subjective cognitive decline, Vascular dementia",

author = "Slot, \{Rosalinde E.R.\} and Sikkes, \{Sietske A.M.\} and Johannes Berkhof and Henry Brodaty and Rachel Buckley and Enrica Cavedo and Efthimios Dardiotis and Francoise Guillo-Benarous and Harald Hampel and Kochan, \{Nicole A.\} and Simone Lista and Tobias Luck and Paul Maruff and Molinuevo, \{Jos{\'e} Luis\} and Johannes Kornhuber and Barry Reisberg and Riedel-Heller, \{Steffi G.\} and Risacher, \{Shannon L.\} and Susanne Roehr and Sachdev, \{Perminder S.\} and Nikolaos Scarmeas and Philip Scheltens and Shulman, \{Melanie B.\} and Saykin, \{Andrew J.\} and Verfaillie, \{Sander C.J.\} and Visser, \{Pieter Jelle\} and Vos, \{Stephanie J.B.\} and Michael Wagner and Steffen Wolfsgruber and Frank Jessen and Merc{\`e} Boada and \{de Deyn\}, \{Peter Paul\} and Roy Jones and Giovanni Frisoni and Luiza Spiru and Flavio Nobili and Yvonne Freund-Levi and Hilkka Soininen and Frans Verhey and Wallin, \{{\AA}sa K.\} and Jacques Touchon and Rikkert, \{Marcel Olde\} and Rigaud, \{Anne Sophie\} and Roger Bullock and Magda Tsolaki and Bruno Vellas and Gordon Wilcock and Lutz Froelich and Hovagim Bakardjian and Habib Benali and Hugo Bertin and Joel Bonheur and Laurie Boukadida and Nadia Boukerrou and Patrizia Chiesa and Olivier Colliot and Bruno Dubois and Marion Dubois and St{\'e}phane Epelbaum and Geoffroy Gagliardi and Remy Genthon and Habert, \{Marie Odile\} and Marion Houot and Aur{\'e}lie Kas and Foudil Lamari and Marcel Levy and Christiane Metzinger and Fanny Mochel and Francis Nyasse and Catherine Poisson and Potier, \{Marie Claude\} and Marie Revillon and Antonio Santos and Andrade, \{Katia Santos\} and Marine Sole and Mohmed Surtee and \{Thiebaud de Schotten\}, Michel and Andrea Vergallo and Nadjia Younsi and \{van der Flier\}, \{Wiesje M.\} and \{Alzheimer's Disease Neuroimaging Initiative\} and \{DESCRIPA working group\} and \{INSIGHT-preAD study group\} and \{SCD-I working group\}",

year = "2019",

month = mar,

doi = "10.1016/j.jalz.2018.10.003",

language = "English",

volume = "15",

pages = "465--476",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia

AU - Slot, Rosalinde E.R.

AU - Sikkes, Sietske A.M.

AU - Berkhof, Johannes

AU - Brodaty, Henry

AU - Buckley, Rachel

AU - Cavedo, Enrica

AU - Dardiotis, Efthimios

AU - Guillo-Benarous, Francoise

AU - Hampel, Harald

AU - Kochan, Nicole A.

AU - Lista, Simone

AU - Luck, Tobias

AU - Maruff, Paul

AU - Molinuevo, José Luis

AU - Kornhuber, Johannes

AU - Reisberg, Barry

AU - Riedel-Heller, Steffi G.

AU - Risacher, Shannon L.

AU - Roehr, Susanne

AU - Sachdev, Perminder S.

AU - Scarmeas, Nikolaos

AU - Scheltens, Philip

AU - Shulman, Melanie B.

AU - Saykin, Andrew J.

AU - Verfaillie, Sander C.J.

AU - Visser, Pieter Jelle

AU - Vos, Stephanie J.B.

AU - Wagner, Michael

AU - Wolfsgruber, Steffen

AU - Jessen, Frank

AU - Boada, Mercè

AU - de Deyn, Peter Paul

AU - Jones, Roy

AU - Frisoni, Giovanni

AU - Spiru, Luiza

AU - Nobili, Flavio

AU - Freund-Levi, Yvonne

AU - Soininen, Hilkka

AU - Verhey, Frans

AU - Wallin, Åsa K.

AU - Touchon, Jacques

AU - Rikkert, Marcel Olde

AU - Rigaud, Anne Sophie

AU - Bullock, Roger

AU - Tsolaki, Magda

AU - Vellas, Bruno

AU - Wilcock, Gordon

AU - Froelich, Lutz

AU - Bakardjian, Hovagim

AU - Benali, Habib

AU - Bertin, Hugo

AU - Bonheur, Joel

AU - Boukadida, Laurie

AU - Boukerrou, Nadia

AU - Chiesa, Patrizia

AU - Colliot, Olivier

AU - Dubois, Bruno

AU - Dubois, Marion

AU - Epelbaum, Stéphane

AU - Gagliardi, Geoffroy

AU - Genthon, Remy

AU - Habert, Marie Odile

AU - Houot, Marion

AU - Kas, Aurélie

AU - Lamari, Foudil

AU - Levy, Marcel

AU - Metzinger, Christiane

AU - Mochel, Fanny

AU - Nyasse, Francis

AU - Poisson, Catherine

AU - Potier, Marie Claude

AU - Revillon, Marie

AU - Santos, Antonio

AU - Andrade, Katia Santos

AU - Sole, Marine

AU - Surtee, Mohmed

AU - Thiebaud de Schotten, Michel

AU - Vergallo, Andrea

AU - Younsi, Nadjia

AU - van der Flier, Wiesje M.

AU - Alzheimer's Disease Neuroimaging Initiative

AU - DESCRIPA working group

AU - INSIGHT-preAD study group

AU - SCD-I working group

PY - 2019/3

Y1 - 2019/3

N2 - Introduction: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non-AD dementia and (2) determinants of progression to dementia. Methods: Eleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated dementia incidence and identified risk factors using Cox proportional hazards models. Results: In SCD, incidence of dementia was 17.7 (95% Poisson confidence interval 15.2-20.3)/1000 person-years (AD: 11.5 [9.6-13.7], non-AD: 6.1 [4.7-7.7]), compared with 14.2 (11.3-17.6) in controls (AD: 10.1 [7.7-13.0], non-AD: 4.1 [2.6-6.0]). The risk of dementia was strongly increased in SCD in a memory clinic setting but less so in a community-based setting. In addition, higher age (hazard ratio 1.1 [95% confidence interval 1.1-1.1]), lower Mini–Mental State Examination (0.7 [0.66-0.8]), and apolipoprotein E ε4 (1.8 [1.3-2.5]) increased the risk of dementia. Discussion: SCD can precede both AD and non-AD dementia. Despite their younger age, individuals with SCD in a memory clinic setting have a higher risk of dementia than those in community-based cohorts.

AB - Introduction: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non-AD dementia and (2) determinants of progression to dementia. Methods: Eleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated dementia incidence and identified risk factors using Cox proportional hazards models. Results: In SCD, incidence of dementia was 17.7 (95% Poisson confidence interval 15.2-20.3)/1000 person-years (AD: 11.5 [9.6-13.7], non-AD: 6.1 [4.7-7.7]), compared with 14.2 (11.3-17.6) in controls (AD: 10.1 [7.7-13.0], non-AD: 4.1 [2.6-6.0]). The risk of dementia was strongly increased in SCD in a memory clinic setting but less so in a community-based setting. In addition, higher age (hazard ratio 1.1 [95% confidence interval 1.1-1.1]), lower Mini–Mental State Examination (0.7 [0.66-0.8]), and apolipoprotein E ε4 (1.8 [1.3-2.5]) increased the risk of dementia. Discussion: SCD can precede both AD and non-AD dementia. Despite their younger age, individuals with SCD in a memory clinic setting have a higher risk of dementia than those in community-based cohorts.

KW - Alzheimer's disease

KW - Dementia incidence

KW - Dementia Lewy bodies

KW - Frontotemporal dementia

KW - Preclinical Alzheimer's disease

KW - Subjective cognitive decline

KW - Vascular dementia

UR - https://www.scopus.com/pages/publications/85056582914

UR - https://www.scopus.com/pages/publications/85056582914#tab=citedBy

U2 - 10.1016/j.jalz.2018.10.003

DO - 10.1016/j.jalz.2018.10.003

M3 - Article

C2 - 30555032

AN - SCOPUS:85056582914

SN - 1552-5260

VL - 15

SP - 465

EP - 476

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 3

ER -

Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia

Abstract

Funding

UN SDGs

Keywords

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this